January 31, 2022
NovelMed's Complement Alternative Pathway Specific Anti-Bb Antibody (NM8074) for Rare Diseases Achieves a Major Milestone
February 21, 2022
NovelMed Announces Interim Positive Results from Its Phase I Clinical Trial of NM8074, a Bb Complement Alternative Pathway Blocker Antibody
April 22, 2022
Bioworld Article "Returning to complement – can NovelMed’s next-gen antibody outperform Ultomiris"_
August 15, 2022
Alternative Pathway Blocker Anti-Bb Antibody (NM8074) Receives US FDA Clearance to Start Efficacy Trial in C3 Glomerulopathy (C3G) Patients
Date, 2022
Title